Corrected info: CTIX market cap 161 million, AVXL market cap 274 million. That previous incorrect figure for AVXL must not have taken their reverse split into account.
Anyway there's no comparison in pipeline and how far along the clinical trials are. CTIX should be valued at much more than AVXL, not at much less. As an AVXL shareholder I'm happy to see that market cap -- but it shows how underpriced CTIX is.
And since AVXL is valued at 1/4 of AXON, whose Alzheimer's drug has already failed in its first attempt at clinical trials, and which has not commenced its announced future trials with lowered expectations, and which has been in existence only a few months -- well, all I can say is, efficient market theory, bah humbug.
Anyway there's no comparison in pipeline and how far along the clinical trials are. CTIX should be valued at much more than AVXL, not at much less. As an AVXL shareholder I'm happy to see that market cap -- but it shows how underpriced CTIX is.
And since AVXL is valued at 1/4 of AXON, whose Alzheimer's drug has already failed in its first attempt at clinical trials, and which has not commenced its announced future trials with lowered expectations, and which has been in existence only a few months -- well, all I can say is, efficient market theory, bah humbug.